Chowdhury Deepro, Chin Laura, Odabashian Roupen, Fawaz Ali, Canil Christina, Ong Michael, Kirchhof Mark G, Reaume Martin Neil, Beltran-Bless Ana-Alicia, Savard Marie-France, Tsoulis David J, Bossé Dominick
Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada.
Cancers (Basel). 2025 Jan 14;17(2):251. doi: 10.3390/cancers17020251.
The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is expanding dramatically. Many of these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus and skin pigmentation changes have also been noted. This review aims to synthesize dermatologic events observed with antibody drug conjugates, poly (ADP-ribose) polymerase (PARP) inhibitors, androgen receptor pathway inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, and the combination of these agents used for the treatment of GU cancers. It provides a guide on diagnosis and initial management of these rashes for medical oncologists.
用于治疗泌尿生殖系统（GU）癌症的可用治疗选择正在急剧增加。其中许多治疗方法具有独特的、有时甚至是严重的皮肤毒性，包括麻疹样、大疱性、脓疱性、苔藓样、湿疹样、银屑病样和掌跖皮疹。瘙痒和皮肤色素沉着变化也已被注意到。本综述旨在综合抗体药物偶联物、聚（ADP-核糖）聚合酶（PARP）抑制剂、雄激素受体途径抑制剂、酪氨酸激酶抑制剂、免疫检查点抑制剂以及这些用于治疗GU癌症的药物组合所观察到的皮肤事件。它为肿瘤内科医生提供了这些皮疹的诊断和初始管理指南。
